95 results about "Platlet-Derived Growth Factor" patented technology

The invention relates to the field of biology, and discloses a serum-free culture medium which essentially comprises an IMDM (Iscove Modified Dulbecco Medium), L-glutamine, sodium bicarbonate, Hepes, recombinant human insulin, recombinant human transferrin, recombinant human albumin, 2-mercaptoethanol, protocatechuic acid, lipid, amino acid, vitamins, trace elements, Pluronic F-68, hydrocortisone, vitamin C, bonding amine or recombinant human fibronectin, progesterone, putrescine, heparin, serotonin, epidermal growth factors (EGFs), b-fibroblast growth factors (FGF), platelet derive growth factor (PDGF)-BB and insulin-like growth factor (IGF)-I. The serum-free culture medium is clear in chemical components, free from animal sources and serum and safe and ideal in cell cultivation and avoids the doped animal components and unstable batches, and the results of the cultured mesenchymal stem cells show that the total cellular score, the cell phenotype and the secretory cell factors are normal, so that the serum-free culture medium has good industrial application prospect.

Materials and methods are provided for producing and using aptamers useful as oncology therapeutics capable of binding to PDGF, PDGF isoforms, PDGF receptor, VEGF, and VEGF receptor or any combination thereof with great affinity and specificity. The compositions of the present invention are particularly useful in solid tumor therapy and can be used alone or in combination with known cytotoxic agents for the treatment of solid tumors. Also disclosed are aptamers having one or more CpG motifs embedded therein or appended thereto.

The invention relates to a bifunctional novel periodontal guided tissue regeneration membrane with a sandwich structure and a preparation method thereof and application. The bifunctional novel periodontal guided tissue regeneration membrane comprises an inner layer, an intermediate layer and an outer layer. The inner layer is a polycaprolactone / silk fibroin / mesoporous bioactive glass microsphere fiber membrane; the intermediate layer is a polycaprolactone / silk fibroin fiber membrane; and the outer layer is a polycaprolactone / silk fibroin fiber membrane loading platelet-derived growth factors. The bifunctional novel periodontal guided tissue regeneration membrane is of a three-layer-membrane structure and can promote periodontal soft tissue regeneration and have functions of periodontal hard tissue and soft tissue dual regeneration and repair; the bifunctional novel periodontal guided tissue regeneration membrane can also effectively prevent the invasion of gingival epithelial cells to a bone defect area and provide a space for regeneration and reconstruction of bone tissues. In addition, the periodontal guided tissue regeneration membrane also has good biocompatibility, biodegradability and biological activity.

The invention discloses a nucleic acid aptamer molecular beacon probe for the detection of platelet-derived growth factor. The nucleic acid aptamer molecular beacon probe comprises a PDGF-BB nucleic acid aptamer, a fluorescent group which connects to the 5' end of the PDGF-BB nucleic acid aptamer and a quenching group which connects to the 3' end of the PDGF-BB nucleic acid aptamer. According to the invention, high specificity and high affinity of the nucleic acid aptamer probe to the target protein and high sensitivity type conversion mechanism are subtly utilized, and fluorescence quenching mechanism is also utilized. The nucleic acid aptamer molecular beacon probe provided by the invention has a high sensitivity and a good selectivity. The detection process by the use of the nucleic acid aptamer molecular beacon probe provided by the invention is simple to operate with only one step, and the operation cost can be reduced.

The invention relates to a chondrocyte culture medium and a chondrocyte culture method. The chondrocyte culture medium can reduce dedifferentiation of the chondrocyte and improve the multiplication capacity of the chondrocyte. The chondrocyte culture medium provided by the embodiment of the invention comprises a basal culture medium, serum with a concentration of 5-20%, a platelet-derived growth factor with a concentration of 1-20 ng/ml, and beta-mercaptoethanol with a concentration of (1-5)*10<-5> M/L.

The invention provides a liquid protein chip kit for detecting a liver fibrosis degree. In the liquid protein chip kit, coupling antibody microspheres comprise 1, fluorescent microspheres coupling with procollagen peptide III and/or a metalloprotease tissue inhibitor factor-1 capture antibody, 2, one or more of fluorescent microspheres coupling with collagen peptide IV, fibronectin, a transforming growth factor-beta 1, a platelet-derived growth factor, a tumor necrosis factor alpha capture antibody, and an angiotensin II capture antibody, and 3, fluorescent microspheres coupling with a serum hyaluronic acid capture antibody and/or a laminin capture antibody. The liquid protein chip kit can realize combined detection of a plurality of liver fibrosis-related markers for reflection of different liver fibrosis stages, can shorten detection time to more than ten minutes from a few hours, can finish detection of a plurality of markers only by 1 microliter of a serum sample, can be operated simply and has a low diagnosis cost.

The invention provides metastatic tumor deletion protein small-molecule cyclopeptide, derivatives or salts thereof, a preparation method for the metastatic tumor deletion protein small-molecule cyclopeptide, the derivatives or salts thereof and an application of the metastatic tumor deletion protein small-molecule cyclopeptide, the derivatives or salts thereof in preparation of antitumor medicaments. The metastatic tumor deletion protein small-molecule cyclopeptide is low in molecular weight, high in stability and very low in toxicity and can enter cells through cell membranes to inhibit endocytosis of tumor cells and interfere morphologic change of the cell membranes and conduction of relevant antitumor signals by inhibiting dimerization of Mtss1 protein, so that cell proliferation and growth caused by tumor stimulating factors such as epidermal growth factors EGF, platelet derived growth factor PDGF or sonic hedgehog (shh) factors are weakened, wherein the in-vitro inhibition activity of nanomole-scale inhibitor-protein can remarkably inhibit the endocytosis of the cells after the inhibitor-protein is directly added into cell culture fluid without being transfected or packaged by lipidosome.

The invention belongs to the field of medical cosmetology, and particularly relates to composition with an anti-aging function and preparation thereof. The composition comprises, by weight, 0.03-4 parts of stem cell growth factors, 1-30 parts of honeysuckle extracts, 50-300 parts of honey and 0.1*10<-3>-1*10<-3> parts of hyaluronic acid. The stem cell growth factors comprise at least two of epidermal growth factors, fiber cell growth factors, platelet-derived growth factors and vascular endothelial growth factors. According to the composition with the anti-aging function and the preparation, multiple stem cell growth factors are added into the composition, the multiplication capacity of epidermis cells is improved remarkably, meanwhile the composition formula is optimized, and the effects of all components in the composition are played effectively, so that the composition has rich nutritional ingredients, the good moisturizing effect and the antioxidant effect, and the composition presents excellent anti-aging effect.

The invention provides a composition with a cell repairing function. The composition per milliliter comprises the following components: (1) a growth factor group which comprises platelet-derived growth factors PDGF greater than 600pg, vascular endothelial growth factors VEGF greater than or equal to 3300pg and stem cell factor receptors SCF R greater than or equal to 750pg; (2) a protein group with the repairing function, wherein the protein group is 0.3-0.8mg based on nitrogen content; and (3) polypeptides and amino acids, wherein the polypeptides and amino acids are 0.5-1.0mg based on nitrogen content. The composition provided by the invention has the excellent cell repairing function and has good preventing and repairing effects on series of diseases or wounds caused by cellular damage. The invention further provides a preparation method and an application of the composition.

The invention discloses a culture medium for adipose derived stem cells. The culture medium for the adipose derived stem cells comprises RPMI-1640 medium, and further comprises 2 to 2.5g/L of D-glucose, 30 to 45mg/L of cholesterol, 0.5 to 0.8g/L of potassium chloride, 0.1 to 0.3 mu g/L of sodium selenite, 8 to 10 mu g/L of taurine, 10 to 20 mu g/L of heparin calcium, 2.2 to 2.5g/L of human serum albumin, 20 to 50mg/L of vascular endothelial growth factors, 3 to 6mg/L of fibroblast growth factors, 40 to 80mg/L of platelet-derived growth factors, 20 to 40mg/L of glutathione, 50 to 100mg/L of vitamins, and 100 to 200mg/L of plant extracts. The culture medium for the adipose derived stem cells disclosed by the invention is free of components of animal origin, has no residues or pollution, has good cell anchorage dependence and high proliferation rate, improves the pathogenic microorganism resistance of the culture medium, and further lowers the cost of the culture medium.

The invention provides a drug/factor control-released thin film scaffold. The drug/factor control-released thin film scaffold is characterized by comprising a film-like bionic scaffold, a PDGF (Platelet Derived Growth Factor) coating layer and a slow release layer which are sequentially arranged. According to a scaffold material, i.e, a film-like scaffold material on the surface layer of a factor/the core layer of a drug, for clinic periodontal treatment, provided by the invention, controlled release of active factors and drugs is realized, and cell proliferation and osteogenic differentiation are promoted, so that three elements of seed cells, a scaffold material and regulatory factors in tissue regeneration are organically combined, periodontal repairing is promoted, and a facilitation function for periodontal tissue engineering research is obtained.

The invention provides a bone-marrow mesenchymal stem cell culture medium and application thereof, and belongs to the technical field of stem cells as well as cell culture and amplification. The bone-marrow mesenchymal stem cell culture medium consists of the following ingredients at the following concentrations: 52-53% by volume of Dulbecco modified MEM medium, 38-42% by volume of MCDB medium, 1XITS cell culture additives, 8-12 microgram/milliliter of linoleic acid, 40-60 microgram/milliliter of human serum albumin, 1X penicillin and streptomycin, 75-125 micromoles of L-ascorbic acid, 1-3% by volume of fetal bovine serum, 10-15 micromoles of dexamethasone, 12-18 ng/mL of platelet-derived growth factors, and 8-12 ng/mL of growth promoting factors. Being adopted, the bone-marrow mesenchymal stem cell culture medium provided by the invention is capable of increasing success rate of clonal culture of bone-marrow mesenchymal stem cells (bMSC); and moreover, the bone-marrow mesenchymal stem cell culture medium is capable of increasing passage times, ensuring relatively high cell purity and improving cell primitivity.

The invention relates to a method for preparing a cartilage angiogenesis inhibiting factor for a scalloped hammerhead shark. During preparation, Pro-Asp-Tyr-Lys-Phe-Lys is obtained through cartilage homogenate of the scalloped hammerhead shark, guanidine hydrochloride extraction, acetone precipitation and grading, enzymolysis, gel filtration chromatography, cell membrane chromatography purification and efficient liquid phase chromatography purification. The angiogenesis inhibiting factor can effectively inhibit angiogenesis of chick chorioallantoic membranes, and has an obvious inhibition function on expression of three angiogenesis promoting factors including the vascular endothelial cell growth factor, the basic fibroblast growth factor and the platelet-derived growth factor of lung cancer tissue of mice suffering from the Lewis lung cancer.

The invention discloses a biological diagnosis marker for central nervous system demyelinating diseases. The biological diagnosis marker refers to platelet-derived growth factors, chemotactic factors 12 and chemotactic factors 14 in cerebrospinal fluid. The central nervous system demyelinating diseases include optic neuritis (ON) and neuromyelitis optica (NMO); disease changes can be evaluated by monitoring the platelet-derived growth factor and the chemotactic factors in cerebrospinal fluid in different phases of the optic neuritis ON so as to judge recovering conditions. A new biological marker can be discovered by detecting levels and changes of platelet-derived growth factors, chemotactic factors 12 and chemotactic factors 14 in cerebrospinal fluids of ON and NMO patients, so that the medullar sheath regeneration capability can be estimated, an experimental basis is provided for the ON and NMO recovery and development, and a new idea is provided for treatment.

The invention belongs to the field of cytobiology and relates to a method for efficiently inducing umbilical cord mesenchymal stem cells to differentiate into Schwann-like cells. The method comprises the following steps of: (1) culturing the umbilical cord mesenchymal stem cells to a sub-fusion state, discarding the old culture solution, and adding culture solution comprising 1 mM of beta-mercaptoethanol to induce overnight; (2) discarding the induction solution, washing with a Dulbecco modified eagle medium (DMEM), and adding all-trans retinoic acid to induce for 60 to 84 hours; and (3) discarding the induction solution, washing with the DMEM, adding composition induction solution comprising 5 to 6 ng/ml of platelet-derived growth factors, 9 to 10 ng/ml of alkaline desmocyte growth factors, 13 to 15 uM of Forskolin and 250 to 260 ng/ml of gliocyte growth factors or 200 to 210 ng/ml of nerve growth factors to induce for 10 to 16 days, and change the solution for one time every other 72 hours. By the method, the inductivity can reach over 90 percent.

The invention discloses a compound shown in the following formula I or pharmaceutically acceptable salt thereof. In the formula I, R1, R2, R3, R4 and R5 are defined in the specification. The invention further discloses a method for preparing the compound which is shown in the formula I. The compound shown in the formula I can be used for inhibiting hepatic stellate cells activated by PDGF (Platelet Derived Growth Factor) so as to reverse hepatic fibrosis.

The invention discloses a preparation method of fluorescent sensor system based on cationic conjugated polymer and iridium complex FRET effect and application thereof and is characterized in that it comprises the synthesis step of the iridium complex; the synthesis step of the cationic conjugated polymer;the cationic conjugated polymer and iridium complexes give rise to FRET and obtain the fluorescence sensor system steps based on the FRET effect of the cationic conjugated polymer and iridium complex; the fluorescence sensor system can be used to detect thrombin, adenosine triphosphate, platelet derived growth factor, cocaine and lysozyme . The invention has the advantages of good specificity, high sensitivity, accurate and reliable results, low cost, high speed and simple process.

The invention relates to a tumor living tissue in-vitro culture system and a corresponding tumor living tissue in-vitro culture method. The tumor living tissue in-vitro culture system comprises a support system for simulating an in-vivo basilemma structure and a blood supply system of tumor, a tumor tissue specimen treatment liquid which is a RPMI1640 culture liquid containing 2mu g/ml of amphotericin, 1000U/ml of penicillin and 1000mu g/ml of streptomycin, and a special culture medium for tumor tissue culture, wherein the culture medium contains 20mu g/L of bFGF (Basic Fibroblast Growth Factor), 20mu g/L of EGF (Epidermal Growth Factor), 10mu g/L of PDGF (Platelet Derived Growth Factor), 10mu g/L of HGF (Hepatocyte Growth Factor), 10mu g/L of IGF (Insulin-like Growth Factor), 10mu g/L of NRG1, 10mu g/L of VEGF (Vascular Endothelial Growth Factor), 5% of fetal calf serum as well as 500U/ml of penicillin and 500mu g/ml of streptomycin on the basis of a mixture solution containing 50 percent of DMEM (Dulbecco Modified Eagle Medium) and 50 percent of HamF 12. The invention provides a systematic solution scheme and an appropriate culture medium for the in-vitro culture of tumor tissue cells.

The invention discloses a serum-free medium for expanding human mesenchymal stem cells, which is based on the medium for culturing stem cells, adding linoleic acid, human AB type serum, and platelet-derived growth factors. The invention also discloses a culture method for human mesenchymal stem cells. The serum-free medium of the present invention uses multiple cytokines in combination reasonably, which not only improves the purification effect of mesenchymal stem cells, but also shows that the morphology of human mesenchymal stem cells is still uniform even after 30 passages, thus ensuring The safety of human mesenchymal stem cells improves the expansion speed of cells, reduces the expansion time and reduces the cost.

The present disclosure provides PDGFRbeta-Fc fusion proteins, or biologically active fragments thereof, comprising an extracellular domain of PDGFRbeta, or a biologically active fragment thereof, a linker and a Fc domain, wherein said fusion protein binds one or more of platelet-derived growth factor ligands with high affinity. The PDGFRbeta-Fc fusion proteins, or biologically active fragments thereof, accordingly, can be used to treat pathological neovascularization and fibrosis, e.g. cancer, ocular neovascular disorders or nephropathies. The disclosure also provides methods for treating ocular neovascular disorders with these fusion proteins without increasing vascular leakage. Such PDGFRbeta-Fc fusion proteins, or biologically active fragments thereof, exhibit increased terminal half time in the eye. Also provided are nucleic acid sequences encoding the foregoing PDGFRbeta-Fc fusion proteins, or biologically active fragments thereof, vectors containing the same, pharmaceutical compositions and kits with instructions for use.

The invention relates to a dasyatis akajei cartilage polypeptide angiogenesis inhibitor, and a rapid preparation method and an application thereof. An amino acid sequence of the angiogenesis inhibitor is Gly-Tyr-Ile-Cys-Pro-Gln-Trp; and the molecular weight of ESI-MS (electrospray ionization mass spectrometry) detection is 865.98Da. The angiogenesis inhibitor is capable of effectively inhibiting angiogenesis of chick chorioallantoic membrane (CAM), and has an obvious inhibiting effect on expression of three pro-angiogenic factors, namely a Lewis lung cancer mice lung cancer tissue-loaded vascular endothelial cell growth factor (VEGF), a basic fibroblast growth factor (bFGF) and a platelet-derived growth factor (PDGF).